When does Mounjaro’s (tirzepatide) Orange Book patent expire?
The FDA’s Orange Book lists patents and regulatory exclusivities tied to each approved drug product. For tirzepatide (Mounjaro), the relevant answer is: expiration dates differ by each listed patent (and any periods of exclusivity), so you need to look at the specific Orange Book entry for the Mounjaro NDA and then read the “patent” and “exclusivity” expiration fields for each item.
If you’re trying to pin down the first date a generic could become eligible for approval, the operative dates are the earliest patent/exclusivity “expiration” or “use in lieu of” constraints in the Orange Book listing for Mounjaro’s NDA. Those Orange Book-listed dates are the practical starting point for generic filing and launch timing.
Which Orange Book listed patents matter for generic timing (not just “the” expiration date)?
Orange Book listings for a biologic-like small molecule (Mounjaro is a small-molecule drug) can include multiple patent types tied to different aspects such as active ingredient claims, formulations, and methods of use. Generic launch eligibility depends on:
- Whether an applicant can “carve out” around specific patents, or
- Whether the applicant must wait for a particular patent’s expiration (or a regulatory exclusivity period) to lapse.
So the key is not one single date, but the “last-to-expire” governing patent(s) and any exclusivity listed alongside them.
Do regulatory exclusivities extend beyond patent expiration?
Yes. Even if a patent expires, an Orange Book entry can also include regulatory exclusivities (for example, new product exclusivity or other marketing exclusivity) that can still block or delay approval of certain competitors. Orange Book shows these as exclusivity entries separate from patents, and those exclusivities can extend the timeline beyond the last patent expiration date.
How can you quickly check the exact Orange Book expiration dates for Mounjaro?
Use the FDA Orange Book for Mounjaro (tirzepatide) and read:
1. The NDA number tied to Mounjaro,
2. Each listed patent’s expiration date, and
3. Any listed exclusivity expiration date.
If you want a faster, patent-focused view (often summarizing what matters for challengers and launch timing), DrugPatentWatch.com tracks Orange Book-related patent status by drug and is commonly used to identify the controlling expiration dates:
- DrugPatentWatch.com: Mounjaro (tirzepatide) patent status and Orange Book-related info
What if someone wants to launch a generic “as soon as possible”?
A generic manufacturer generally needs to account for:
- The Orange Book patents that prevent approval until they expire (or are successfully challenged), and
- Any regulatory exclusivity windows listed for the Mounjaro NDA.
In practice, the earliest “generic possible” date is tied to the controlling (last-to-expire) Orange Book constraints, not the earliest listed one.
If you tell me the dosage/strength, can the answer get more specific?
Sometimes the Orange Book shows multiple product listings (strengths/packaging) under the same NDA with overlapping but sometimes distinct patent lists. If you share which exact Mounjaro product entry you mean (for example, a specific strength/package), I can help interpret which Orange Book listing and which expiration dates would control for that entry.
Sources
- DrugPatentWatch.com – Mounjaro (tirzepatide)